RE-DUAL Deals Another Blow to Triple Therapy

    loading  Checking for direct PDF access through Ovid

Abstract

In this trial of post-percutaneous coronary intervention patients with atrial fibrillation, dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor showed lower rates of bleeding but similar ischemic and thrombotic outcomes compared to a triple therapy regimen with warfarin.

Related Topics

    loading  Loading Related Articles